Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
18F-0502B
- Development stage
- Unknown
- Lead developer
- Xuanwu Hospital
- Modality
- Alpha Emitters → Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Beta Emitters → Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
18F-0502B is a novel radiopharmaceutical and positron emission tomography (PET) imaging tracer designed to selectively target and bind to **alpha-synuclein (α-syn)** aggregates in the brain. The accumulation of pathological alpha-synuclein is a key biological marker for a group of neurodegenerative disorders known as synucleinopathies, which include Parkinson's disease (PD), Multiple System Atrophy (MSA), and Dementia with Lewy Bodies (DLB). By utilizing the fluorine-18 isotope for radioactive signaling, 18F-0502B allows clinicians and researchers to non-invasively visualize and quantify the density and distribution of α-syn deposits. This capability is intended to facilitate early diagnosis, monitor disease progression, and assist in the differential diagnosis of movement disorders and dementias related to synuclein pathology.
- Other names
- [18F]0502B[18F]F0502B
02
Targets
Amyloid fibrilsTau aggregates (Microtubule-associated protein tau (pathological form))aggregated α-syn (Alpha-synuclein (α-syn))
Beyond the preview
Go deeper on 18F-0502B.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 18F-0502B.